Exosens Shares Bounce Back 5.05% to €61.35, Second Highest Rise in SBF 120
Exosens shares surged by 5.05% to €61.35 in mid-morning trading, marking one of the strongest gains in the SBF 120. The night vision and imaging technology specialist for defense is regaining ground after several challenging weeks. Meanwhile, the benchmark index has moved up by 0.63% to 6,113.57 points.
A Significant Rebound Bringing the Share Closer to Its 20-Day Moving Average
Exosens shares climbed 5.05% to €61.35, marking its best session in several weeks. This rebound partially erases last week’s decline, bringing the seven-day performance back to +5.05%. Year-on-year, the stock still shows a solid gain of +58.12%. Technically, the price is approaching the 20-day moving average (€62.21), remaining slightly below it (-1.38%). The RSI at 40 has moved out of the low zone reached last week, when the stock had entered an oversold state around €57. The 200-day average at €51.60 remains well below the current price, reflecting the underlying bullish trend. In today's rankings, Exosens holds the second position in the SBF 120, behind Atos (+8.41%) and ahead of Exail Technologies (+4.81%).
Tight Valuation at 32 Times Earnings Before May 22 General Meeting
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Recent developments are marked by the first quarter results published on April 29, showing a revenue increase of 19.7% to €122.6 million and an adjusted gross margin improvement. Last week, the group also announced the consolidation of its brands Photonis, Xenics, and Telops under the Exosens umbrella. In terms of valuation, the stock is trading at approximately 32.6 times the expected earnings for the current fiscal year and 27.5 times those of the next fiscal year, according to a consensus of eight analysts updated on May 16. The average in the industrial sector is at 17.8 times. Earnings per share growth is expected at +18.4% from one fiscal year to the next. The shareholding structure remains significantly influenced by the presence of company executives and founders, with 31.3% held by insiders and 46.1% by institutional investors. The next key event is scheduled for May 22 with the annual general meeting, followed by the half-year results on July 28.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.